The findings showed lower risks of death, intensive care unit admission, and need for ventilation among Paxlovid recipients.
Paxlovid led to better outcomes in hospitalized COVID cohort than Veklury or both drugs
Published in COVID-19
More from COVID-19More posts in COVID-19 »
- Very few US adults getting new flu, COVID, RSV vaccines, even in nursing homes
- US respiratory virus activity remains low ahead of holiday season
- Antiviral COVID-19 drug molnupiravir tied to large drop in deaths in older patients
- Adults with migraines at higher risk of depression during pandemic, study shows